SLE is a classic autoimmune disease, during a flare, lupus may affect the skin, joints, kidney, brain, lung, heart and gastrointestinal tract. Approximately half of all SLE patients experience kidney inflammation. Visfatin is a recently discovered adipocytokine. In addition to its potential role in glucose metabolism and atherosclerosis, visfatin has been linked with inflammation. The study included 40 female patients all were diagnosed as activity of SLE from El Kasr El Aini hospital and 20 healthy female individuals as a control group. All clinical and laboratory data were recorded, including visfatin using ELISA kits. We tested the correlation between visfatin and different variables. There is a highly significant positive correlation between visfatin level and degree of severity of lupus according to the SLEDAI. There is also a highly significant negative correlation between visfatin level and C3 and C4 and that confirms the significant correlation between visfatin level and degree of severity of SLE. We found also in our study that there is a highly significant positive correlation between visfatin level and urea, creatinine, 24 hours Urinary proteins in gm/day which indicate that visfatin level increases significantly in cases of active lupus nephritis.